NCT02834013 2026-06-03Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting798 enrolled
NCT07467772 2026-05-22Ph 2 Elacestrant in ER Positive Uterine SarcomasDana-Farber Cancer InstitutePhase 2 Recruiting30 enrolled